MedPath

Tagged News

Alchemab Therapeutics Initiates Phase 1 Trial of ATLX-1282 and Secures $32 Million Series A Extension

Monoclonal Antibody
  • Alchemab Therapeutics has initiated a Phase 1 first-in-human study of ATLX-1282, marking the first clinical candidate from their AI-enabled platform that identifies protective antibodies from disease-resilient individuals.
  • The company secured a $32 million Series A extension financing, bringing total Series A investment to $114 million, with participation from Eli Lilly, Ono Venture Investment, and existing investors.
  • ATLX-1282 was licensed to Eli Lilly in May 2025 under an exclusive global agreement, with Alchemab conducting the Phase 1 study and Lilly leading further development and commercialization.
  • The additional funding will advance ATLX-2847, a wholly-owned first-in-class program targeting the prostaglandin pathway for muscle atrophy, into clinical development.

Novartis Acquires Tourmaline Bio for $1.4 Billion to Advance Anti-Inflammatory Cardiovascular Therapy

Monoclonal Antibody
  • Novartis agreed to acquire New York-based biotech Tourmaline Bio for $1.4 billion, paying $48 per share in cash, representing a 60% premium to the company's Monday closing price.
  • The acquisition centers on Tourmaline's lead candidate pacibekitug, an anti-IL-6 IgG2 antibody targeting atherosclerotic cardiovascular disease, which could address a significant unmet medical need.
  • The deal strengthens Novartis's cardiovascular portfolio as the company faces generic competition for key drugs including top-selling heart medicine Entresto later this year.
  • The transaction has received board approval from both companies and is expected to close in the fourth quarter of 2025.

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

NCT06362759Active, Not RecruitingPhase 2
Tourmaline Bio, Inc.
Posted 5/15/2024

Novartis Acquires Tourmaline Bio for $1.4 Billion to Strengthen Cardiovascular Pipeline with Pacibekitug

Monoclonal Antibody
  • Novartis announced the acquisition of Tourmaline Bio for approximately $1.4 billion, offering $48 per share in cash to complement its cardiovascular disease portfolio.
  • The acquisition centers on pacibekitug, a promising monoclonal antibody targeting systemic inflammation that represents a major risk factor for cardiovascular disease.
  • Pacibekitug is currently in advanced Phase 2 trials and is considered a Phase 3-capable product that could address high unmet medical needs in cardiovascular care.
  • The transaction is expected to close in the fourth quarter of 2025, subject to regulatory approvals and the tender of a majority of outstanding Tourmaline shares.

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

NCT06362759Active, Not RecruitingPhase 2
Tourmaline Bio, Inc.
Posted 5/15/2024

KBI Biopharma Partners with Infinimmune to Advance Human-First Antibody Manufacturing for Atopic Dermatitis

Monoclonal Antibody
  • KBI Biopharma and Infinimmune have announced a collaboration to advance manufacturing of IFX-101, a human monoclonal antibody targeting atopic dermatitis designed for superior efficacy with extended dosing intervals.
  • Infinimmune's GLIMPSE platform uses a protein language model trained on native human antibody sequences to engineer antibodies that harness evolution-proven strategies with enhanced biologic properties.
  • The IFX-101 program is progressing at KBI's Cell Line Development Center of Excellence in Geneva, Switzerland, utilizing the company's SUREmAb monoclonal antibody development and manufacturing platform.
  • The collaboration combines Infinimmune's human-first antibody discovery approach with KBI's development and manufacturing expertise to rapidly advance toward clinical trials.

Regeneron's First-in-Class Allergen-Blocking Antibodies Show 52% Reduction in Cat Allergy Symptoms in Phase 3 Trials

Monoclonal Antibody
  • Regeneron's investigational allergen-blocking antibodies achieved significant symptom reduction in Phase 3 trials, with cat allergy treatments reducing ocular itch by 52% and birch allergy treatments reducing itch by 51% compared to placebo.
  • Both combination therapies demonstrated rapid onset of action within one week and maintained durable benefits for at least three months following a single subcutaneous administration.
  • The first-in-class approach targets specific allergens directly rather than requiring years of desensitization shots, with additional Phase 3 development planned for cat allergies in the first half of 2026.
  • Both treatments were generally well-tolerated with no serious treatment-related adverse events or trial discontinuations reported in the studies.

Junshi Biosciences' IL-17A Inhibitor JS005 Meets Primary Endpoints in Phase 3 Psoriasis Trial

Monoclonal Antibody
  • Junshi Biosciences announced that JS005, an anti-IL-17A monoclonal antibody, successfully met both co-primary endpoints and key secondary endpoints in a Phase 3 trial for moderate to severe plaque psoriasis.
  • The multi-center, randomized, double-blind, placebo-controlled study conducted across 60 clinical sites in China demonstrated statistically significant and clinically meaningful improvements in PASI 90 and sPGA scores at Week 12.
  • The company plans to submit a new drug application to regulatory authorities in the near future, potentially offering a new treatment option for the approximately 125 million psoriasis patients worldwide.
  • JS005 works by binding to IL-17A with high affinity and selectively blocking its interaction with receptors, thereby inhibiting downstream inflammatory pathways associated with autoimmune diseases.

Adagene's Masked Anti-CTLA-4 Therapy ADG126 Shows 30% Response Rate in Treatment-Resistant Colorectal Cancer

Monoclonal Antibody
  • Adagene's ADG126, a masked anti-CTLA-4 therapy, achieved a ~30% objective response rate with durable responses in microsatellite stable colorectal cancer patients who had failed previous treatments.
  • The combination of ADG126 with pembrolizumab demonstrated over 80% disease control and a median overall survival of 19.4 months in the 10 mg/kg cohort.
  • The therapy maintained a favorable safety profile with less than 20% Grade 3 treatment-related adverse events, potentially enabling higher and more frequent dosing than traditional CTLA-4 inhibitors.
  • Results will be presented at the 2025 Chinese Society of Clinical Oncology Meeting, representing a potential breakthrough for MSS colorectal cancer, which comprises approximately 85% of colorectal cancer cases.

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

NCT04322539CompletedPhase 3
Hutchison Medipharma Limited
Posted 8/12/2020

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

NCT05405595RecruitingPhase 1
Adagene Inc
Posted 6/15/2022

A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)

NCT02314819CompletedPhase 3
Hutchison Medipharma Limited
Posted 12/1/2014

Dupilumab and Remibrutinib Emerge as New Treatment Options for Chronic Spontaneous Urticaria

Monoclonal AntibodyDrug Approval
  • Recent phase 3 trial data reveals dupilumab and remibrutinib as promising alternatives to omalizumab for chronic spontaneous urticaria patients inadequately controlled with antihistamines.
  • Dupilumab achieved complete response rates of 13-31% at week 24, while remibrutinib demonstrated 28-31% complete response rates at week 12, increasing to 36% at week 24.
  • Real-world pilot data shows dupilumab provides modest symptom improvement in omalizumab-resistant patients, with mean UCT scores rising from 6.5 to 8.4 after one month of treatment.
  • All three biologics showed favorable safety profiles with rare serious adverse events and infrequent treatment discontinuations due to side effects.

Florida Cancer Specialists Presents Real-World Evidence Studies on Blood Cancers at SOHO 2025

Real World EvidenceCAR-TMonoclonal Antibody
  • Florida Cancer Specialists & Research Institute presented four abstracts at the Society for Hematologic Oncology 2025 annual meeting, showcasing real-world evidence studies on myelofibrosis and myelodysplastic syndromes.
  • The research includes a retrospective analysis of baseline clinical factors impacting overall survival in myelofibrosis patients and treatment patterns for luspatercept in lower-risk myelodysplastic syndromes.
  • FCS operates more than 150 active clinical trials and has participated in studies for the majority of new cancer drugs approved in the U.S. prior to FDA approval.
  • The organization leverages proprietary real-world datasets and advanced data science to transform clinical data into insights that improve clinical decision-making and patient outcomes.

Purple Biotech Raises $6 Million in Public Offering to Advance Novel Cancer Immunotherapy Pipeline

Monoclonal Antibody
  • Purple Biotech completed a $6 million public offering with potential for an additional $12 million through warrant exercises to fund development of its oncology therapeutic candidates.
  • The company is advancing three innovative cancer therapies: CAPTN-3 tri-specific antibodies, CM24 monoclonal antibody, and NT219 dual inhibitor targeting tumor immune evasion.
  • CM24 demonstrated clear efficacy improvements in a Phase 2 pancreatic cancer study when combined with nivolumab and chemotherapy across all endpoints.
  • NT219 showed anti-tumor activity in combination with cetuximab for recurrent head and neck cancer patients in Phase 1 trials.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.